2025 年前三季度，中国创新药产业迎来关键转折期。有机构表示，创新药头部先盈利，前三季度多家创新药企业核心产品持续商业化放量。此外，叠加政策体系完善与全球流动性宽松共振，产业盈利拐点显现，长期价值回归趋势明确，中国创新药正从 “研发投入期” 迈向 “价值兑现期”。核心产品的商业化突破成为业绩增长的核心引擎。如百济神州的泽布替尼交出亮眼答卷，前三季度全球销售额达 199.50 亿元，逼近 200...
Source Link2025 年前三季度，中国创新药产业迎来关键转折期。有机构表示，创新药头部先盈利，前三季度多家创新药企业核心产品持续商业化放量。此外，叠加政策体系完善与全球流动性宽松共振，产业盈利拐点显现，长期价值回归趋势明确，中国创新药正从 “研发投入期” 迈向 “价值兑现期”。核心产品的商业化突破成为业绩增长的核心引擎。如百济神州的泽布替尼交出亮眼答卷，前三季度全球销售额达 199.50 亿元，逼近 200...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.